Table 2.
Prevalence of mutations in full cohort of non-acral cutaneous melanomas.
| Mutation | No. of pt (%) | Mutation | No. of pt (%) |
|---|---|---|---|
| BRAFV600 | 398 (43.0%) | HNF1A | 9 (1.0%) |
| NRAS | 195 (21.1%) | RET | 9 (1.0%) |
| TP53 | 180 (19.4%) | STK11 | 8 (0.9%) |
| BRAFNon-V600 | 60 (6.5%) | CSF1R | 7 (0.8%) |
| CDKN2A | 59 (6.4%) | GNAS | 7 (0.8%) |
| PTEN | 36 (3.9%) | EZH2 | 6 (0.6%) |
| KIT | 35 (3.8%) | MLH1 | 5 (0.5%) |
| ERBB4 | 34 (3.7%) | SMAD4 | 5 (0.5%) |
| EGFR | 31 (3.3%) | SMARCB1 | 5 (0.5%) |
| KDR | 30 (3.2%) | SMO | 5 (0.5%) |
| IDH1 | 27 (2.9%) | ABL1 | 4 (0.4%) |
| CTNNB | 24 (2.6%) | AKT1 | 4 (0.4%) |
| KRAS | 24 (2.6%) | FGFR1 | 4 (0.4%) |
| ATM | 18 (1.9%) | NOTCH1 | 4 (0.4%) |
| APC | 16 (1.7%) | GNAQ | 3 (0.3%) |
| PKI3CA | 16 (1.7%) | SRC | 3 (0.3%) |
| RB1 | 16 (1.7%) | JAK2 | 2 (0.2%) |
| FLT3 | 15 (1.6%) | JAK3 | 2 (0.2%) |
| MET | 15 (1.6%) | VHL | 2 (0.2%) |
| PTPN11 | 15 (1.6%) | ALK | 1 (0.1%) |
| FBXW7 | 13 (1.4%) | ERBB2 | 1 (0.1%) |
| HRAS | 13 (1.4%) | GNA11 | 1 (0.1%) |
| FGFR2 | 11 (1.2%) | MPL1 | 1 (0.1%) |
| PDGFRA | 11 (1.2%) | NPM1 | 1 (0.1%) |
| FGFR3 | 9 (1.0%) |